Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) By Type- ALD and NAFLD ALD Stages - Alcoholic Steatosis and Alcoholic Steatohepatitis NAFLD Stages - Non Alcoholic Steatosis and NASH By Region- North America, Europe, Asia Pacific and ROW By Country - United States, Canada, United Kingdom, Germany, France, India, Japan, China, Saudi Arabia, South Africa, Brazil. July 2017
Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH) By Type Global Coverage By NAFLD Stages Scope of the Study g Regional Coverage By ALD Stages Country Coverage By Type of Drugs Global Coverage Regional Coverage North America Fatty Liver Disease Market By Europe Value (2012-2022) Asia Pacific Breakdown-By Type (2012-2021) ROW ALD NAFLD Breakdown By NAFLD Stages (2012- Fatty Liver Disease Market - By 2022): (Steatosis, NASH) Value (2012-2016) Breakdown By ALD Stages (2012-2022): (Steatosis, Alcohol Hepatitis) Fatty Liver Disease Market By Breakdown by ALD drugs(2012- Value (2017-2022) 2022): (Opoid Antagonist Fatty Liver Disease Market By,Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony Type (2012-2022) stimulating factor) Fatty Liver Disease Market By Breakdown By NAFLD Drug(2012- ALD Drugs ( 2012-2022) 2022) : (Antioxidants Thiazolidinedione, Biguanides, Fatty Liver Disease Market- By Hypolipidemic Agents, FXR receptor NAFLD Drug agonist, Elafibranoer) Region (North America, Europe, APAC and ROW ) Country (U.S., Canada, China, Japan, India, Germany, France, United Kingdom, Saudi Arabia, South Africa, Brazil,) Country Coverage Company Coverage U.S. Canada Pfizer Germany Conatus France Novartis U.K. Intercept pharmaceuticals China Allergan Japan Immuron India Takeda Brazil Gilead sciences South Africa Genfitt South Arabia Product Benchmarking Fatty Liver Disease Market : By Product Sales Benchmarking Value (2012-2022) Business Sales Overview Fatty Liver Disease Market : By Business Product Launches Overview & Recent Type, By Value (2012-2022) Product Approvals Launches & Recent Approvals Merger & Acquisition Merger & Acquisition 2
Table of Content S. No Particulars Page No. 1. Research Methodology 22 2. Executive Summary 23 3. Strategic Recommendation 24 3.1 Focus on Asia Region 25 3.2 Focus on drug development for NASH and Alcohol Hepatitis 26 3.3 Focus on early Stage detection of Alcohol and Non Alcoholic Steatosis 27 4. Fatty Liver Market Outlook 28 5. Global Fatty Liver Disease Market: Growth and Forecast 36 5.1 By Value (2012-2016) 37 5.2 By Value (2017-2022) 38 6 Global Fatty Liver Disease By Type 39 6.1 Global Fatty Liver Disease Market -By Type (Alcoholic Fatty Liver Disease (ALD), Non Alcoholic Fatty Liver Disease (NAFLD)): Breakdown(%) 39 6.1.1 Global Fatty Liver Disease Market-By Type,2016 (%) 40 6.1.2 Global Fatty Liver Disease Market-By Type,2022 (%) 41 6.2 Global Fatty Liver Disease By Type, By Value 42 6.2.1 Global Alcoholic Fatty Liver Disease Market 42 6.2.1.1 By Value (2012-2022) 42 3
Table of Content S. No Particulars Page No. 6.2.2 Global Non Alcoholic Fatty Liver Disease Market 44 6.2.2.1 By Value (2012-2022) 44 7. Global Alcoholic Fatty Liver Disease Market By Stages 47 7.1 Global Alcoholic Fatty Liver Disease Market -By Stages (Alcoholic Steatosis and Alcoholic Steatohepatitis): Breakdown(%) 47 7.1.1 Global Alcoholic Fatty Liver Disease Market -By Stages, 2016 (%) 48 7.1.2 Global Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%) 49 7.2 Global Alcoholic Fatty Liver Disease Market -By Stages, By Value 50 7.2.1 Global Alcoholic Steatosis Market 50 7.2.1.1 By Value (2012-2022) 50 7.2.2 Global Alcoholic Steatohepatitis Market 52 7.2.2.1 By Value (2012-2022) 52 8. Global Non Alcoholic Fatty Liver Disease Market By Stages 54 8.1 Global Non Alcoholic Fatty Liver Disease Market -By Stages (Non Alcoholic Steatosis and Non Alcoholic Steatohepatitis ) : Breakdown(%) 54 8.1.1 Global Non Alcoholic Fatty Liver Disease Market -By Stages, 2016(%) 55 8.2.1 Global Non Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%) 56 4
Table of Content S. No Particulars Page No. 8.2 Global Non Alcoholic Fatty Liver Disease Market -By Stages, By Value 57 8.2.1 Global Non Alcoholic Steatosis Market 57 8.2.1.1 By Value (2012-2022) 57 8.2.2 Global Non Alcoholic Steatohepatitis Market 58 8.2.2.1 By Value (2012-2022) 58 9. Global Alcoholic Fatty Liver Disease Market By Drugs 61 9.1 Global Alcoholic Fatty Liver Disease Market -By Drugs (Opoid Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor) : Breakdown(%) 61 9.1.1 Global Alcoholic Fatty Liver Disease Market -By Drugs, 2016(%) 62 9.1.2 Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2022 (%) 63 9.2 Global Alcoholic Fatty Liver Disease Market -By Drugs, By Value 64 9.2.1 Global Opioid Antagonist Drug Market 64 By Value (2012-2022) 64 9.2.2 Global Pentoxifylline Drug Market 66 By Value (2012-2022) 66 9.2.3 Global Glucocorticoid Drug Market 67 By Value (2012-2022) 67 5
Table of Content S. No Particulars Page No. 9.2.4 Global Antioxidants Drug market 69 9.2.4.1 By Value (2012-2022) 69 9.2.5 Global Granulocyte colony stimulating factor Drug Market 71 9.2.5.1 By Value (2012-2022) 71 10. Global Non Alcoholic Fatty Liver Disease Market By Drugs 73 10.1 Global Non Alcoholic Fatty Liver Disease Market -By Drugs (Antioxidants, Thiazolidinedione, Biguanides, Lipid Lowering Agents, FXR Receptor Agonist, Elafibranor ) : Breakdown(%) 73 10.1.1 Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2016(%) 74 10.2.1 Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2022 (%) 75 10.2 Global Non Alcoholic Fatty Liver Disease Market -By Drugs, By Value 76 10.2.1 Global Antioxidants Drug Market 76 10.2.1.1 By Value (2012-2022) 76 10.2.2 Global Thiazolidinedione Drug Market 78 10.2.2.1 By Value (2012-2022) 78 10.2.3 Global Biguanides Drug Market 80 10.2.3.1 By Value (2012-2022) 80 6
Table of Content S. No Particulars Page No. 10.2.4 Global Hypolipidemic Agents Drug market 82 10.2.4.1 By Value (2012-2022) 82 10.2.5 Global FXR Receptor Agonist Drug Market 84 10.2.5.1 By Value (2012-2022) 84 10.2.6 Global Elafibranor Drug Market 86 10.2.6.1 By Value (2012-2022) 86 11. Global Fatty Liver Disease Market Pipeline Analysis (By developer, Phase and indication) 88 12. Global Fatty Liver Disease Market Regional Analysis 93 12.1 Global Fatty Liver Disease Market -By Regional : Breakdown(%) 93 12.1.1 Global Fatty Liver Disease Market -By Region, 2016(%) 94 12.1.2 Global Fatty Liver Disease Market -By Region, 2022 (%) 95 13. North America Fatty liver Disease Market 96 13.1 By Value (2012-2022) 97 13.2 North America Fatty liver Disease Market By Type, By Value 100 13.3 North America Fatty liver Disease Market By ALD Drug, By Value 102 7
Table of Content S. No Particulars Page No. 13.4 North America Fatty liver Disease Market By NAFLD Drug, By Value 104 14. North America Fatty Liver Disease Market By Country Analysis 105 14.1 North America Fatty Liver Disease Market By Country,2012-2016(%) 106 14.2 North America Fatty Liver Disease Market By Country,2017E-2022F(%) 106 14.3 United States Fatty Liver Disease Market By Value(2012-2022) 107 14.3.1 United States Fatty Liver Disease Market By Type, By Value 109 14.4 Canada Fatty Liver Disease Market By Value(2012-2022) 110 14.4.1 Canada Fatty Liver Disease Market By Type, By Value 111 15. Asia Pacific Fatty liver Disease Market 113 15.1 By Value (2012-2022) 114 15.2 Asia Pacific Fatty liver Disease Market By Type, By Value 117 15.3 Asia Pacific Fatty liver Disease Market By ALD Drug, By Value 119 15.4 Asia Pacific Fatty liver Disease Market By NAFLD Drug, By Value 121 16. Asia Pacific Fatty Liver Disease Market By Country Analysis 122 16.1 Asia Pacific Fatty Liver Disease Market By Country,2012-2016(%) 123 16.2 Asia Pacific Fatty Liver Disease Market By Country,2017E-2022F(%) 123 8
Table of Content S. No Particulars Page No. 16.3 India Fatty Liver Disease Market By Value(2012-2022) 124 16.3.1 India Fatty Liver Disease Market By Type, By Value 126 16.4 China Fatty Liver Disease Market By Value(2012-2022) 127 16.5 Japan Fatty Liver Disease Market By Value(2012-2022) 129 16.5.1 Japan Fatty Liver Disease Market By Type, By Value 130 16.6 Rest of Asia Fatty Liver Disease Market-By Value(2012-2022) 131 17. Europe Pacific Fatty liver Disease Market 132 17.1 By Value (2012-2022) 133 17.2 Europe Fatty liver Disease Market By Type, By Value 137 17.3 Europe Fatty liver Disease Market By ALD Drug, By Value 139 17.4 Europe Fatty liver Disease Market By NAFLD Drug, By Value 141 18. Europe Fatty Liver Disease Market By Country Analysis 142 18.1 Europe Fatty Liver Disease Market By Country,2012-2016(%) 143 18.2 Europe Fatty Liver Disease Market By Country,2017E-2022F(%) 143 9
Table of Content S. No Particulars Page No. 18.3 United Kingdom Fatty Liver Disease Market By Value(2012-2022) 144 18.3.1 United Kingdom Fatty Liver Disease Market By Type, By Value 145 18.4 Germany Fatty Liver Disease Market By Value(2012-2022) 147 18.4.1 Germany Fatty Liver Disease Market By Type, By Value 149 18.5 France Fatty Liver Disease Market By Value(2012-2022) 150 18.5.1 France Fatty Liver Disease Market By Type, By Value 151 18.6 Rest of Europe Fatty Liver Disease Market-By Value(2012-2022) 152 19. Rest of World Fatty liver Disease Market 153 19.1 By Value (2012-2022) 154 19.2 Rest of World Fatty liver Disease Market By Type, By Value 156 19.3 Rest of World Fatty liver Disease Market By ALD Drug, By Value 158 19.4 Rest of World Fatty liver Disease Market By NAFLD Drug, By Value 160 20. Rest of World Fatty Liver Disease Market By Country Analysis 161 20.1 Rest of World Fatty Liver Disease Market By Country,2012-2016(%) 162 20.2 Rest of World Fatty Liver Disease Market By Country,2017E-2022F(%) 162 10
Table of Content S. No Particulars Page No. 20.3 Saudi Arabia Fatty Liver Disease Market By Value(2012-2022) 163 20.3.1 Saudi Arabia Fatty Liver Disease Market By Type, By Value 164 20.4 South Africa Fatty Liver Disease Market By Value(2012-2022) 166 20.4.1 South Africa Fatty Liver Disease Market By Type, By Value 168 20.5 Brazil Fatty Liver Disease Market By Value(2012-2022) 169 20.5.1 Brazil Fatty Liver Disease Market By Type, By Value 170 20.6 Others Fatty Liver Disease Market-By Value(2012-2022) 171 21. Market Dynamics 172 21.1 Drivers 173 21.2 Challenges 177 22. Market Trends 180 23. Policy and Regulations 182 24. Porter Five Force 190 25. SWOT Analysis 192 26. Company Profiling 194 11
Table of Content S. No Particulars Page No. 26.1 Pfizer 195 26.2 Conatus Pharmaceuticals 197 26.3 Novartis 198 26.4 Intercept Pharmaceuticals 200 26.5 Allergan 201 26.6 Immuron 202 26.7 Takeda 203 26.8 Gilead Sciences 205 26.9 Genfit 207 27. About Us 208 12
List of Figures Figure No. Figure Title Page No. Figure 1: History of Fatty Liver Disease 31 Figure 2: Therapeutic Algorithm for Management of Alcoholic Hepatitis 32 Figure 3: Treatment Algorithm of NAFLD 35 Figure 4: Global Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Million) 37 Figure 5: Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million) 38 Figure 6: Global Fatty Liver Disease Market Size, By Type, 2016 (%) 40 Figure 7: Global Fatty Liver Disease Market Size, By Type, 2022F (%) 41 Figure 8: Global Alcoholic Fatty liver Market Service Market, By Value, 2012-2016 (USD Billion) 42 Figure 9: Global Alcoholic Fatty liver Market Service Market, By Value, Forecast, 2017E-2022F (USD Billion) 42 Figure 10: Beer Consumption, Billion Liters, 2014 43 Figure 11: Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, 2012-2016 (USD Billion) 44 Figure 12: Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, Forecast, 2017E-2022F (USD Billion) 44 Figure 13: Global Diabetic Population, By Region, 2015 (Million) 46 Figure 14: Global Alcoholic Liver Disease Market Size, By Stage, 2016 (%) 48 Figure 15: Global Alcoholic liver Disease Market Size, By Type, 2022F (%) 49 Figure 16: Global Alcoholic Steatosis Treatment, By Value, 2012-2016 (USD Billion) 50 Figure 17: Global Alcoholic Steatosis Treatment, By Value, Forecast, 2017E-2022F (USD Billion) 50 Figure 18: World Alcohol Consumption, Liters per Capita, 2014-2016 51 Figure 19: Global Alcoholic Staetohepatitis Market, By Value, 2012-2016 (USD Billion) 52 13
List of Figures Figure No. Figure Title Page No. Figure 20: Global Alcoholic Staetohepatitis Market, By Value, Forecast, 2017E-2022F (USD Billion) 52 Figure 21: Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2016 (%) 55 Figure 22: Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2022F (%) 56 Figure 23: Global Non Alcoholic Steatosis Treatment Market, By Value, 2012-2016 (USD Billion) 57 Figure 24: Global Non Alcoholic Steatosis Treatment Market, By Value, Forecast, 2017E-2022F(USD Billion) 57 Figure 25: Global NASH Market, By Value, 2012-2016 (USD Billion) 58 Figure 26: Global NASH Market, By Value, Forecast, 2017E-2022F (USD Billion) 58 Figure 27: Global Alcoholic Fatty Liver Market Size, By Drug, 2016 (%) 62 Figure 28: Global In-flight Catering Service Market Size, By Airline Type, 2022F (%) 63 Figure 29: Global Opioid Antagonist Drug Market, By Value, 2012-2016 (USD Billion) 64 Figure 30: Global Opioid Antagonist Drug Market, By Value, Forecast, 2017E-2022F(USD Billion) 64 Figure 31: Global Pentoxifylline Drug Market, By Value, 2012-2016 (USD Billion) 66 Figure 32: Global Pentoxifylline Drug Market, By Value, Forecast, 2017E-2022F(USD Billion) 66 Figure 33: Global Glucocoticoid Drug Market, By Value, 2012-2016 (USD Billion) 67 Figure 34: Global Glucocorticoid Drug Market, By Value Forecast, 2017E-2022F(USD Billion) 67 Figure 35: Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)\ 69 Figure 36: Global Antioxidants Drug Market, By Value,, Forecast, 2017E-2022F(USD Billion) 69 Figure 37: Global Granulocyte Colony Stimulating Factor Drug Market, By Value, 2012-2016 (USD Billion) 71 Figure 38: Global Granulocyte Colony Stimulating Factor Drug Market, By Value, Forecast, 2017E-2022F(USD Billion) 71 Figure 39: Global Non Alcoholic Fatty Liver Market Size, By Drug, 2016 (%) 74 14
List of Figures Figure No. Figure Title Page No. Figure 40: Global Non Alcoholic Fatty Liver Market Size, By Drug, 2022F (%) 75 Figure 41: Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion) 76 Figure 42: Global Antioxidants Drug Market, By Value, Forecast, 2017E-2022 (USD Billion) 76 Figure 43: Global Thiazolidinedione Drug Market, By Value, 2012-2016 (USD Billion) 78 Figure 44: Global Thiazolidinedione Drug Market, By Value, Forecast, 2017E-2022F(USD Billion) 78 Figure 45: Global Biguandies Drug Market, By Value, 2012-2016 (USD Billion) 80 Figure 46: Global Biguandies Drug Market, By Value, Forecast, 2017E-2022F(USD Billion) 80 Figure 47: Global Hypolipidemic Drug Market, By Value, 2012-2016 (USD Billion) 82 Figure 48: Global Hypolipidemic Drug Market, By Value, Forecast, 2017E-2022F(USD Billion) 82 Figure 49: Global FXR Receptor Agonist Drug Market, By Value, 2012-2016 (USD Billion) 84 Figure 50: Global FXR Receptor Agonist Drug Market, By Value, Forecast, 2017E-2022F (USD Billion) 84 Figure 51: Global Elafibranor Drug Market, By Value, 2012-2016 (USD Billion) 86 Figure 52: Global Elafibranor Drug Market, By Value, Forecast, 2017E-2022F (USD Billion) 86 Figure 53: Global Fatty Liver Disease Market Size and Share, By Region, 2016 94 Figure 54: Global Fatty Liver Disease Market Size and Share, By Segments, 2022F 95 Figure 55: North America Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 97 Figure 56: North America Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 97 Figure 57: North America Healthcare Expenditure, 2011-2014 (% of GDP) 98 Figure 58: North America Population Age 15-64 2015 (% of Total) 98 Figure 59: North America Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 100 Figure 60: North America Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion) 102 15
List of Figures Figure No. Figure Title Page No. Figure 61: North America Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion) 104 Figure 62: North America Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total) 106 Figure 63: North America Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total) 106 Figure 64: United States Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 107 Figure 65: United States Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 107 Figure 66: Percentage of United states adults who had at least one heavy drinking day,2011-2015 108 Figure 67: United States Alcohol Liters Per Capita Consumption, 2011-2015 108 Figure 68: United States Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 109 Figure 69: CanadaFatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 110 Figure 70: Canada Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 110 Figure 71: Canada Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 111 Figure 72: Canada Alcohol Liters Per Capita Consumption, 2011-2015 112 Figure 73: Prevalence of Obese and overweight Population, By Age,2014(% ) 112 Figure 74: Asia Pacific Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 114 Figure 75: Asia PacificFatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 114 Figure 76: Obesity Prevalence in Asian Countries, 2014 (%) 115 Figure 77: Asia Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 117 Figure 78: Asia Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion) 119 Figure 79: Asia Pacific Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion) 121 Figure 80: Asia Pacific Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total) 123 16
List of Figures Figure No. Figure Title Page No. Figure 81: Asia Pacific Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total) 123 Figure 82: India Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 124 Figure 83: India Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 124 Figure 84: Percentage of United states adults who had at least one heavy drinking day, 2011-2015 125 Figure 85: India Alcohol Liter per capita Consumptions, 2015-2016 125 Figure 86: India Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 126 Figure 87: China Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 127 Figure 88: China Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 127 Figure 89: Health expenditure in China,2011-2015 (USD Billion) 128 Figure 90: China Alcohol Liter per capita Consumptions,2015-2016 128 Figure 91: Japan Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 129 Figure 92: Japan Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 129 Figure 93: Japan Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 130 Figure 94: Rest of Asia Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 131 Figure 95: Rest of Asia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 131 Figure 96: Europe Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 133 Figure 97: Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 133 Figure 98: Europe Diabetes Prevalence, By Country, 2015 (% of Population Aged 20 to 79) 134 Figure 99: EU Health Expenditure Per Capita, 2011-2014 (USD) 135 Figure 100: Breakdown of Total Health Expenditure in Europe (%) 135 17
List of Figures Figure No. Figure Title Page No. Figure 101: Europe Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 137 Figure 102: Europe Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion) 139 Figure 103: Europe Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion) 141 Figure 104: Europe Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total) 143 Figure 105: Europe Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total) 143 Figure 106: United Kingdom Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 144 Figure 107: United Kingdom Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 144 Figure 108: United Kingdom Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 145 Figure 109: Alcohol Related Disease Death, 2015 146 Figure 110: Diabetes Prevalence in U.K. 2015 146 Figure 111: Five Day Drinking Prevalence By Age, (%), 2014-2015 146 Figure 112: Germany Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 147 Figure 113: Germany Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 147 Figure 114: Private Healthcare Spending in Germany, US Dollar/capita 2011 to 2015 148 Figure 115: Diabetes Prevalence in 55-74 age people in Germany, Forecast 2030F. 148 Figure 116: Alcohol Consumption per capita,2012-2016 (liter) in Germany 148 Figure 117: Germany Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Million) 149 Figure 118: France Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 150 Figure 119: France Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 150 Figure 120: France Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Million) 151 18
List of Figures Figure No. Figure Title Page No. Figure 121: Rest Of Europe Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 152 Figure 122: Rest of Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 152 Figure 123: Rest of World Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 154 Figure 124: Rest of World Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 154 Figure 125: Rest of World Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 156 Figure 126: Rest of World Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 158 Figure 127: Rest of world Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion) 160 Figure 128: Rest of World Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total) 162 Figure 129: Rest of World Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total) 162 Figure 130: Saudi Arabia Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 163 Figure 131: Saudi Arabia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 163 Figure 132: Saudi Arabia Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 164 Figure 133: Saudi Arabia Prevalence of Obesity Forecast 2022 (%) 165 Figure 134: South Africa Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 166 Figure 135: South Africa Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 166 Figure 136: South Africa Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 168 Figure 137: Brazil Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion) 169 Figure 138: Brazil Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 169 Figure 139: Brazil Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) 170 Figure 140: Others Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) 171 19
List of Figures Figure No. Figure Title Page No. Figure 141: Others Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) 171 Figure 142: Pfizer Segmental Breakup, 2016(%) 196 Figure 143: Pfizer Sales, By Region, 2016 (%) 196 Figure 144: Novartis Sales, By Segment 2015 (%) 199 Figure 145: Novartis Sales, By Region,2015 (%) 199 Figure 146: Novartis Pharmaceuticals Sales, By Franchise, 2015 (%) 199 Figure 147: Takeda Segmental Breakup 204 Figure 148: Takeda Revenue, 2013-2016 (USD Million) 204 Figure 149: Gilead Sciences Product Sales, 2016 (%) 206 Figure 150: Gilead Sciences HCV Product Sales, 2014-2016 (USD Billion) 206 20
List of Tables Table No. Table Title Page No. Table A: Causes of NAFLD Infection 33 Table B: Quantity of Alcohol in Standard Drink 51 Table C: Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication 89 Table D: Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication 90 Table E: Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication 91 Table F: NASH Multi Therapy Treatment Market Analysis, By Drug, Developer, Phase, Indication, Status 92 21
Research Methodology Research Definition Global Fatty Liver Disease Treatment Market Report comprises of the study of various aspects of Fatty Liver Market and forecast until 2022. Global Fatty Liver Disease Treatment Market has been segmented on basis of Types(Alcoholic and Non Alcoholic Fatty Liver); Alcoholic Fatty Liver By Stages (Alcoholic Steatosis and Alcoholic Steatohepatitis ), Non Alcoholic Fatty Liver Stages By Stages (Alcoholic Steatosis and Non Alcoholic Steatohepatitis), By Region (North America, Europe, APAC, Middle East and ROW) and By Country (U.S., Canada, Germany, Russia, United Kingdom, China, India, Japan, Brazil, Mexico, Saudi Arabia, South Africa and UAE) Data Analysis and Interpretation Our historic market trend has been figured out by various paid databases which was further triangulated with inputs and insights from industry experts, companies and stakeholders, through primary research (manufacturers, marketing managers, others). Back-of-the-Envelope calculation for the market estimation has been made through proper understanding of the market as well as future business strategies of the companies operating in the market. The Report has covered only two stages drug treatment for Alcoholic and Non alcoholic fatty liver. Azoth Analytics has conducted quantitative as well as qualitative research to gather market insights such as market sizing, market segmentation, recent trends and developments and competitive landscape. Our team has conducted extensive primary surveys by reaching out industry experts across the value chain of the global orthopeadic market. Companies Contacted: St Stephen Hospital Delhi 22
Global Fatty Liver Disease Market Overview Global Fatty liver Disease market in the forecasted period will witness rapid growth owing to several NASH Drug expected to enter the market in forecasted period. Figure : Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million) CAGR: xxxx% 2017E 2018F 2019F 2020F 2021F 2022F Source: Azoth Analytics Estimates Xxxx Xxxx Xxxx. Xxxx Xxxx xxxx 23
Global Non Alcoholic Liver Disease Market-By Stages NASH treatment held the majority market share of approximately 81.67%, by value, in the year 2016. Figure : Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2016 (%) Key Drivers Non Alcoholic Steatosis Xxxxx xxxxx Non Alcoholic Steatohepatitis Xxxxx xxxxx Source: Azoth Analytics Estimates 24
Global North Heart America Valve Repair Fatty Liver Devices Disease Market, Market By Value Figure : North America Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion) CAGR 2012-2015 xxxx% Figure : North America Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion) CAGR 2016-2022 xxxx% 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Xxxx Xxxx Source: Azoth Analytics Estimates. Xxxx Xxxx xxxx 25
Japan Fatty Liver Disease Market, By Type Figure 93: Japan Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) CAGR 2012-2016 Alcoholic Fatty Liver Disease: xxxx% Non Alcoholic Fatty Liver Disease : xxxx% CAGR 2017-2022 Alcoholic Fatty Liver Disease: xxxx% Non Alcoholic Fatty Liver Disease : xxxx% 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Source: Azoth Analytics Estimates Xxxxx Xxxxx Xxxxx xxxxx 26
Europe Fatty Liver Disease Market, By NFALD Drug Figure : Europe Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion) CAGR 2012-201 Antioxidants: xxxx% Thiazlolidinedione: xxxx% Biguandies: xxxx% HypolipidemicAgents: xxxx% FXR Receptor Agonist: xxxx% Elafibranor: xxxx % CAGR 2017-2022 Antioxidants: xxxx% Thiazlolidinedione: xxxx% Biguandies: xxxx% Hypolipidemic agents: xxxxx% FXR Receptor Agonist: xxxxx% Elafibranor: xxxx% 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Source: Azoth Analytics Estimates Xxxx Xxxx Xxxx 27
About Azoth Analytics Pvt Ltd. Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy services. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts). Related Reports: Global Vitreoretinal Surgery Devices Market (By Product, By End User, By Region, By Country): Opportunities and Forecast (2016-2021) By Product (Vitrectomy Machines & Packs, Photocoagulation Surgery Devices, Illumination Devices, Others); By End User (Hospitals, Free Standing Ambulatory Surgery Center); By Region (North America, Europe, APAC, ROW); By Country (US, Canada, Mexico, UK, Germany, France, Japan, China, India, Brazil, South Africa) Global Biomaterials Market (By Type, By Application, By Region): Opportunities and Forecasts (2016-2021) - (By Material Type Polymer, Ceramic, Metal; By Application - Orthopaedic, Cardiovascular, Plastic Surgery, Wound Care); By Region-North America, Europe, APAC, ROW; By Country US, UK, Germany, Italy, Japan, China, India; Key Players Strategy, Financial Performance) Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis provided in the report are meant for customers internal use only and not for general publication or disclosure to third parties. 28